BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 15018709)

  • 1. The N-terminal of the V3 loop in HIV type 1 gp120 is responsible for its conformation-dependent interaction with cell surface molecules.
    Ling H; Usami O; Xiao P; Gu HX; Hattori T
    AIDS Res Hum Retroviruses; 2004 Feb; 20(2):213-8. PubMed ID: 15018709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection.
    Sakaida H; Hori T; Yonezawa A; Sato A; Isaka Y; Yoshie O; Hattori T; Uchiyama T
    J Virol; 1998 Dec; 72(12):9763-70. PubMed ID: 9811711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
    Verrier F; Borman AM; Brand D; Girard M
    AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
    Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
    Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of gp120 of human immunodeficiency virus by their V3 loop-derived peptides.
    Ling H; Zhang XY; Usami O; Hattori T
    Biochem Biophys Res Commun; 2002 Sep; 297(3):625-31. PubMed ID: 12270140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
    Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
    PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V3 loop of human immunodeficiency virus type 1 suppresses interleukin 2-induced T cell growth.
    Sakaida H; Murakami T; Kawamata S; Hattori T; Uchiyama T
    AIDS Res Hum Retroviruses; 1997 Jan; 13(2):151-9. PubMed ID: 9007200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
    Polzer S; Dittmar MT; Schmitz H; Schreiber M
    Virology; 2002 Dec; 304(1):70-80. PubMed ID: 12490404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.
    Ghaffari G; Tuttle DL; Briggs D; Burkhardt BR; Bhatt D; Andiman WA; Sleasman JW; Goodenow MM
    J Virol; 2005 Nov; 79(21):13250-61. PubMed ID: 16227248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for coreceptor selectivity by the HIV type 1 V3 loop.
    Cardozo T; Kimura T; Philpott S; Weiser B; Burger H; Zolla-Pazner S
    AIDS Res Hum Retroviruses; 2007 Mar; 23(3):415-26. PubMed ID: 17411375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
    Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
    Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.
    Hoffman TL; LaBranche CC; Zhang W; Canziani G; Robinson J; Chaiken I; Hoxie JA; Doms RW
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6359-64. PubMed ID: 10339592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of the V3 region of gp120 with SDF-1 preserves the infectivity of T-cell line-tropic human immunodeficiency virus type 1.
    Yonezawa A; Hori T; Takaori-Kondo A; Morita R; Uchiyama T
    J Virol; 2001 May; 75(9):4258-67. PubMed ID: 11287575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
    Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
    Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated region.
    Platt EJ; Kuhmann SE; Rose PP; Kabat D
    J Virol; 2001 Dec; 75(24):12266-78. PubMed ID: 11711617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of biotinylated V3 loop peptides of human immunodeficiency virus type 1 to flow cytometric analyses and affinity chromatographic techniques.
    Murakami T; Matsushita S; Maeda Y; Takatsuki K; Uchiyama T; Hattori T
    Biochim Biophys Acta; 1993 Apr; 1181(2):155-62. PubMed ID: 8481404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures.
    Antell GC; Dampier W; Aiamkitsumrit B; Nonnemacher MR; Jacobson JM; Pirrone V; Zhong W; Kercher K; Passic S; Williams JW; Schwartz G; Hershberg U; Krebs FC; Wigdahl B
    Retrovirology; 2016 May; 13(1):32. PubMed ID: 27143130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.